The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Roche says its new assay “resolves this challenge by delivering accurate and specific results
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
76 of 180 long COVID-associated genes also linked to ME
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Subscribe To Our Newsletter & Stay Updated
